Cargando…

P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research

Detalles Bibliográficos
Autores principales:	Mark, D, Middelkoop, K, Roux, S, Gray, G, Mlisana, K, Nchabaleng, M, Churchyard, G, De Bruyn, G, Latka, M, Magagula, D, Kublin, J, Allen, M, Bekker, L
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767709/ http://dx.doi.org/10.1186/1742-4690-6-S3-P214

Ejemplares similares

Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women
por: Latka, Mary H., et al.
Publicado: (2012)

P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine
por: Latka, M, et al.
Publicado: (2009)

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
por: Volk, JE, et al.
Publicado: (2012)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial
por: de Bruyn, G, et al.
Publicado: (2009)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
por: Allen, MA, et al.
Publicado: (2009)

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
por: Moodie, Zoe, et al.
Publicado: (2015)

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa
por: Lazarus, Erica Maxine, et al.
Publicado: (2014)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
por: Koblin, B, et al.
Publicado: (2012)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
por: Hyman, David M., et al.
Publicado: (2015)

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
por: Fong, Youyi, et al.
Publicado: (2018)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial
Publicado: (2022)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009)

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
por: deCamp, Allan C., et al.
Publicado: (2017)

2896. Oral PrEP Uptake among HVTN 704/HPTN 085 Participants: Implications for the Future of Biomedical HIV Prevention Trials
por: Cantos, Valeria D, et al.
Publicado: (2023)

Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa
por: Slack, Catherine, et al.
Publicado: (2007)

Enrolling Women into HIV Preventive Vaccine Trials: An Ethical Imperative but a Logistical Challenge
por: Mills, Edward, et al.
Publicado: (2006)

497. Identification of Patients at Risk of Clostridium difficile Infection for Enrollment in Vaccine Clinical Trials
por: Stevens, Vanessa, et al.
Publicado: (2018)

The Impact of Educational Intervention on Willingness to Enroll in a Clinical Trial of a Gonorrhea Vaccine
por: Penlington, Michael, et al.
Publicado: (2023)

COVID-19 trial co-enrolment and subsequent enrolment
por: Gertner, Elie
Publicado: (2020)

Contraceptive Use in Women Enrolled into Preventive HIV Vaccine Trials: Experience from a Phase I/II Trial in East Africa
por: Kibuuka, Hannah, et al.
Publicado: (2009)

Review of preventative HIV vaccine clinical trials in South Africa
por: Laher, Fatima, et al.
Publicado: (2020)

Prediction of clinical trial enrollment rates
por: Bieganek, Cameron, et al.
Publicado: (2022)

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
por: Fuchs, Jonathan D., et al.
Publicado: (2015)

Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context
por: Lhomme, Edouard, et al.
Publicado: (2019)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

Involving patients in enrolment decisions for acute myocardial infarction trials
por: Dickert, Neal W, et al.
Publicado: (2015)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

HIV vaccines beyond COVID‐19: merits of trust
por: Kublin, James G
Publicado: (2021)

What discontinued trials teach us about trial registration?
por: Vellinga, Akke, et al.
Publicado: (2021)

Enrollment of Diverse Populations in the INGENIOUS Pharmacogenetics Clinical Trial
por: Shah-Williams, Ebony, et al.
Publicado: (2020)

Disparities in patient enrollment on glioblastoma clinical trials
por: Liu, Yang, et al.
Publicado: (2020)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d1gbvcl5u52o2qutfsdthr9k40